Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Fibrous scars drive glioblastoma recurrence

Fibrous scars drive glioblastoma recurrence

Carcinotech dominates summer awards season

Carcinotech dominates summer awards season

16 promising postdoctoral scientists awarded Damon Runyon Fellowships for cancer research

16 promising postdoctoral scientists awarded Damon Runyon Fellowships for cancer research

Novel biochip diagnoses deadly brain cancer in under an hour

Novel biochip diagnoses deadly brain cancer in under an hour

Engineered NK cells with IL-21 show strong antitumor activity against glioblastoma

Engineered NK cells with IL-21 show strong antitumor activity against glioblastoma

Study links renalase-1 and T-cell receptor interaction to increased melanoma survival

Study links renalase-1 and T-cell receptor interaction to increased melanoma survival

Drug shows new promise in treating breast cancer with brain metastases or recurrent glioblastoma

Drug shows new promise in treating breast cancer with brain metastases or recurrent glioblastoma

Decoding glioblastoma: New insights into molecular subtypes and mesenchymal transition mechanisms

Decoding glioblastoma: New insights into molecular subtypes and mesenchymal transition mechanisms

From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas

From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas

Harnessing oncolytic viruses for cancer immunotherapy to improve treatment outcomes

Harnessing oncolytic viruses for cancer immunotherapy to improve treatment outcomes

UCLA launches groundbreaking clinical trial for vaccine targeting aggressive pediatric brain cancer

UCLA launches groundbreaking clinical trial for vaccine targeting aggressive pediatric brain cancer

Active immune cells discovered in brain's cranial bone marrow fighting glioblastomas

Active immune cells discovered in brain's cranial bone marrow fighting glioblastomas

Breakthrough research identifies pathway used by glioblastoma to infiltrate the brain

Breakthrough research identifies pathway used by glioblastoma to infiltrate the brain

AI reprograms glioblastoma cells into dendritic cells for cancer immunotherapy

AI reprograms glioblastoma cells into dendritic cells for cancer immunotherapy

Discovery of potent immune cells near glioblastomas opens new avenues for treatment

Discovery of potent immune cells near glioblastomas opens new avenues for treatment

Insilico Medicine unveils Science42:DORA to streamline academic writing and research

Insilico Medicine unveils Science42:DORA to streamline academic writing and research

UCLA scientists awarded $300,000 grant to study glioblastoma microenvironment

UCLA scientists awarded $300,000 grant to study glioblastoma microenvironment

Electrical currents could supercharge cancer-killing immune cells, study finds

Electrical currents could supercharge cancer-killing immune cells, study finds

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

New technique could one day be used to target glioblastoma

New technique could one day be used to target glioblastoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.